Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A major trial that aimed to see if a common bone-strengthening drug could help prevent recurrences of breast cancer found it did not benefit most patients, doctors said Thursday.
The five-year study, known as the AZURE trial, followed 3,360 women with advanced breast cancer who had already undergone surgery.
The study randomly assigned some to take the osteoporosis drug Zometa, also known as zoledronic acid, in addition to standard therapy. Zometa is made by the Swiss pharmaceutical giant Novartis.
The hope was that it would prevent cancer from resurfacing, as it often does, in a survivor's bones.
But the American Association for Cancer Research said the drug was found to have no impact on "disease-free survival" for the group as a whole.
"In the larger population, we did not see a difference," said Robert Coleman, professor of medical oncology at the University of Sheffield in England, who presented the results at a conference in San Antonio, Texas.
He added, however, that there was a slight difference across age groups, with older patients faring slightly better on the drug.
The 30 percent of the group who were post-menopausal by at least five years, 1,101 in all, saw a 29 percent improvement in overall survival, which was "unlikely to be a chance finding," Coleman said.
"We will clearly want to investigate further in this population."
He added, however, that "the young patients are getting no benefit. If anything they are doing worse."
Zoledronic acid is a bisphosphonate that works by lowering the amount of calcium released by the bones into the blood.
It is used to treat high blood calcium levels that can coincide with cancer and also to prevent fractures in patients with cancer.
ksh/jk
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments